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1. INTRODUCTION 
Liquid chromatography (LC) is an analytical chromatographic technique that has long been 
used in the separation of sample mixtures. As the first type of chromatography discovered, 
over time its advancement has lead to the improvement of chromatographic performance 
during analytical procedures. High-Performance Liquid Chromatography is one of the most 
widely used chromatographic techniques for determination of drugs in pharmaceutical 
preparations, drug bio-analysis and food products analysis. The latest upgrade on 
chromatographic systems entails that of Ultra High-Performance Liquid Chromatography 
(UPLC). It is one of the most sophisticated instruments utilized in analytical procedures 
nowadays. This avant-garde technology has successfully demonstrated an increase in 
laboratory productivity and chromatographic performance efficiency, which is the reason of 
its high applicability in world-leading scientific laboratories. 
In this dissertation the development and validation of a new method for determination of 
related substances in an active pharmaceutical ingredient (Bromhexine Hydrochloride) using 
UPLC has been discussed. The method was transferred from the conventional procedure 
using HPLC guided by European Pharmacopeia. Several optimizations of chromatographic 
conditions have been carried out in order to combine the most optimal ones to be used for 
analysis. Testing the linearity, precision, accuracy and selectivity of analytical procedure 
ensured the validity of the newly developed method. 
Furthermore, the apparatuses, principal of work and the differences on chromatographic 






2. AIM OF WORK 
 
 
The objective of the work was to develop a new method for determination of Bromhexine 
Hydrochloride active pharmaceutical ingredient (API) using Ultra High-Performance Liquid 
Chromatography in favor of increasing the analytical performance efficiency in comparison 
to conventional method using HPLC. The newly developed method should spare the usage of 
large volumes of organic solvents and shorten the analysis time, while preserving a reliable 
chromatographic performance during method validation, with resulting satisfactory 



























3. THEORETICAL PART 
 
3.1 Instrumentation and Analytical Methods 
3.1.1 High performance liquid chromatography 
 
HPLC is a form of liquid chromatography and the most commonly used chromatographic 
technique for determination of drugs in pharmaceutical preparations, drug bio-analysis and 
food products analysis. It is a separation technique utilized to analyze, identify, quantify and 
purify the individual components of sample mixture. 
 
3.1.1.1 General Principle 
 
 HPLC is a highly sophisticated system, consisting of four main parts: the solvent delivery 
system, the separation column, the detector and the data system. The column comprise of the 
stationary phase of densely packed particles. The mobile phase is pumped at a constant flow 
rate against the high pressure through the column and the sample mixture is injected into the 
flowing mobile phase just prior to the column inlet. Analytes are separated on the basis of 
their affinity to the stationary phase and depending on their individual migration speeds, they 
elute from the column at different times and are thus separated. The equilibrium distribution 
of each compound between the stationary phase and mobile phase determines the differential 
migration of each of them through column. The distribution constant (KC) is dependent on the 
composition of both phases and also the temperature in the column oven. 
 






Equation 1. Distribution Constant[1] 
        
Where, Cs is the concentration of analyte on the stationary phase 
                     Cm is the concentration of analyte on the mobile phase 
 
 The pumps provide high operational pressure (instead of gravity) to deliver the mobile phase 
and sample contents through the porous material of stationary phase in the column, hence the 
name High Pressure Liquid Chromatography. The detector is a device used to visualize the 
analytes on a chromatogram. The computer system prints the resulting chromatograms and 
can also provide an automated process of the whole analysis, which is one of the main 





Figure 3.1 HPLC apparatus diagram[2] 
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Retention time (tR) is the amount of time elapsed during which analytes travel from the 
injection site in the column to the detector. Retention times are depicted in chromatogram 
against the detector signal and they are different for each compound. (tM) is the time elapsed 
for the mobile phase to pass through the column cavity. 
 
 
Figure 3.2 Chromatogram with analyte and mobile phase retention times[3] 
 
3.1.1.2 Parameters affecting the chromatographic performance 
 
Retention factor (k) also known as capacity factor, is the degree of retention of sample 
component in the column and is defined as the time the solute resides in the stationary phase 
(tR), relative to the time it resides in the mobile phase (tM)[4]: 
 
    
      
  
  
Equation 2. Retention factor (k) 
Retention factors are distinct for every chemical identity and they usually lie in the range 
between 2-5, except for samples of high molecular complexity, where the retention factor 
range needs to be higher to have satisfactory separation results. 
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Selectivity factor also known as separation factor (α), describes the separation of two 
compounds. It measures the separation selectivity of components for the specific 




                  
Equation 3. Selectivity factor 
The value of selectivity factor has to be more than 1, in order to have a good separation of the 
peaks in chromatogram. 
 
Figure 3.3 Chromatograms showing the influence of selectivity factor on peak separation[5] 
Manipulating with the composition of mobile phase, column temperature and composition of 
stationary phase the selectivity factor can be increased to improve the separation process. 
Flow rate of mobile phase is adjusted before starting the analysis. Dependent on the diameter 
of the column, the flow rate should be set in order to have a linear velocity of mobile phase in 
the column. Linear velocity (V) is the speed at which the solvent front travels the length of 
the column (L), and is calculated by dividing the column length by the retention time (t0) of 




        
Equation 4 Linear velocity    
 
  When the samples are injected in the column the analytes collect at the top and they descend 
by gradually blocking the column. This results in a an increase in backpressure, which can 
compromise the analysis process by decreasing the flow rate, thus it is important to keep the 
flow rate constant in order to have a constant gradual blockage of the column. The range of 
flow rate is 0.01-10ml/min, but the typical flow rate used is 0.5-2.0ml/min[1]. 
Temperature. Column oven temperature should be kept constant to have satisfactory results 
of separation performance. Higher temperatures can improve the process of segregation, 
although temperatures above 60°C are rarely employed due to possible degradation of 
stationary phase and mobile phase evaporation. Unless, otherwise specified in individual 
monographs, columns are used at ambient temperatures[7]. 
Particle size.  Columns are composed of an inside porous material of packed micro-particles, 
with usual average particle diameter of 3μm, 5μm or 10μm. The particle size is an important 
parameter on controlling the backpressure of the column and the separation efficiency. 
Column backpressure and column efficiency are inversely proportional to the square of the 
particle diameter, meaning that as the particle size decreases, the column backpressure and 
efficiency increase[8]. The smaller particle size columns are more suitable for more complex 
mixtures with similar components due to higher separation efficiency, while the larger ones 
are used more frequently for analysis of compounds with greater structural differences. 
Physical dimensions. Typical column lengths used in HPLC are 5, 10, 15, 25cm. Long 
columns provide increased efficiency and resolution, but their drawback stands in long 
retention times of analytes and increased backpressure. The internal diameter (ID) of the 
column is also very important factor influencing the performance. Columns of smaller 
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internal diameter size support higher sensitivity due to higher concentration of the analyte in 
mobile phase and their advantage stands on the reduced flow rate and mobile phase volume 
needed to reach the same optimal linear velocity without increasing the analysis time. A 
study on the efficiency of columns with different ID but same column length (238mm) at 
constant flow-rate shows the performance of columns with ID 4.6mm, 4.0mm, 3.2mm and 
2.1. It was observed that in columns with ID 4.0mm and 3.2mm the reduction in plate height 
(HEPT) was the lowest, the 3.2mm ID column had higher reduction and the 2.1mm ID 
column had the highest reduction in HEPT. On the other hand columns with ID 4.0mm and 
3.2mm showed increased efficiency for low concentrated sample, while the 4.6mm ID 
column showed highest load capacity and the 2.1mm ID column showed lowest load 
capacity[9]. Column length (L) and internal diameter (ID) determine the volume bed (V) i.e. 
the minimum volume of mobile phase required to elute an unretained analyte from the 
column[8]. 
Column efficiency . The separation efficiency of analytes in the column is determined by the 
extent to which the compounds are spread in the column. If the analytes spread to a large 
extend in relation to their retention times, the peaks will have wider bands meaning that the 
column wasn’t as efficient on separation. The narrow peaks indicate high column efficiency. 
In order to have optimal separation, peak broadening should be limited. Band broadening is 
expressed by the number of the theoretical plates (N) in the column. As the name suggests, 
these plates are theoretical separations of layers of columns, where the distribution of the 
sample and mobile phase undergo through separate equilibrations[10]: 
 
       
  
    
      
Equation 5. Theoretical plates                
 tR   - retention time of analyte 





Figure 3.4 Number of theoretical plates[11] 
The separation efficiency increases with the increasing number of theoretical plates, hence 
the formula for individual height of theoretical plates in relation to column length and plate 
number: 
 
     
 
 
                                                                       L- length of column 
Equation 6. Height equivalent to theoretical plates[10]               N- number of plates                        
 
The smaller the HETP, the larger the value of N hence, the column efficiency increases.  
Resolution- the degree of separation of two peaks is defined as resolution, RS [1]: 
 
 
   
           
     
  
Equation 7. Peak resolution 
tR1  , tR2  - retention times of two components in chromatogram 
W1, W2 - corresponding peak width at half peak height 
 
There are three parameters to be considered to achieve high resolution: 
 




   
 
) (
     
   
)           
 
 
N – reducing the particle size of stationary phase, also reduces the HETP will be reduced and 
in turn increases N; 
k’– manipulating with composition of mobile phase to improve retention factor 
α – optimize selectivity factor (mobile phase, column t (°C), stationary phase) 
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Asymmetry factor (AS) is used to determine the peak symmetry: 
 
 
                         
 
Figure 3.5. Asymmetry factor; Tailing Factor[12] 
W0,05  - peak width in 1/20 of its height 
AC    - the distance between the perpendicular and the rising part of the peak 
BC    - the distance between the perpendicular and the decreasing part of the peak 
 





3.1.1.3 Operational modes and stationary phases 
 
The separations are achieved based on the different interactions of analytes to stationary and 
mobile phases. Depending on the type of the stationary and mobile phases used, there are 
several modes of separations:  
 Ion exchange is based on charge-charge interactions between ionic groups of analytes and 
oppositely charged functional groups bound to the stationary phase. The mobile phase 
usually consists of aqueous buffers or ionic solutions and it’s suitable for analysis of 
charged biological molecules such as: alkaloids [e.g. nicotine determination on hair of 
active smokers[13]]; proteins [e.g. detection of thalassemia/hemoglobin variants evaluated 
in a prospective study in a tertiary care center in north India [14]]; inorganic ions etc. 
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 Size exclusion chromatography (SEC) is based on the elution of solutes by mobile phase 
through the porous material of the column, without interacting with the stationary phase. 
In this manner the small molecules will be able to penetrate both the porous particles and 
the inter-particle volume, resulting in longer retention time; while the larger molecules can 
only penetrate the inter-particle volume due to their size, thus will be eluted faster from 
the column and be placed first in the chromatogram. Mobile phases used can be aqueous 
buffers or organic solvents. SEC is mostly used to determine large biological molecules 
and in polymer characterization [e.g. gyration distribution of polystyrene, 
polyphosphazenes and poly (ethylene oxide) using SEC[15]]. 
 Affinity chromatography is characterized with a specific ligand bound to the stationary 
phase. The protein(s) to be analyzed will therefore interact by means of hydrogen bonding, 
Van Der Waal’s and/or electrostatic forces with their specific ligand and be successfully 
separated with the highest selectivity and resolution provided by this method. Now days 
there are many current studies aiming the design and manufacture of novel ligands tailored 
to specific biotechnological needs, by utilizing combinatory chemistry and molecular 
modeling[16]. 
 Chiral chromatography is solely employed to separate chiral molecules from their racemic 
mixture. The principle includes the usage of chiral stationary phases, i.e. a single 
enantiomer bound to the achiral matrix of stationary phase such as silica gel or various 
oligosaccharides (cellulose, cyclodextrines). When eluted through column, the enantiomers 
of the analyte will exert different affinity to the single enantiomer bound to the stationary 
phase, therefore their retention times will differ in the resulting chromatogram. Screening 
for new chiral stationary phases to improve the analysis and separation of chiral 
pharmaceutical drugs by different HPLC modes is increasing vastly. A strategy employing 
RP-HPLC using cellulose/amylose stationary phase, was successfully applied to set 37 
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diverse chiral pharmaceuticals. Satisfactory enantioselectivity was achieved for 89% of 
them[17]. 
 Adsorption. The analytes along with a non-polar mobile phase (e.g. hexane) compete for 
adsorption sites of polar stationary phase (silica) in the column. Analytes with no affinity to 
polar sites will be retained from column together with mobile phase. Since adsorption is a 
reversible reaction, if polarity of mobile phase is increased, it would interfere the analyte-
stationary phase interaction resulting in a faster elution of the compound.  
 Partition is based in hydrophobic interaction of the non-polar stationary phase with analytes 
and the polar mobile phase. This is principle used very often in Reversed Phase HPLC  
 
3.1.1.4 Reversed Phase HPLC 
 
Stationary phase in most cases consists of derivatized silica with non-polar functional groups 
to the silanol moieties using chlorosilanes or other silane reagents[1]. There are many 
hydrophobic functional groups used to manipulate the silica matrix, with Octadecyl (C18) 
being the most favorable one considering it’s high hydrophobicity. The free silanol groups 
left unreacted due to the steric hindrance of three alkyl groups in the silicum atom are treated 
further with trimethylsilylating reagents, in the process called endcapping. These reagents 
react with remaining silanol groups and they also provide protective shield on the stationary 
phase. From frequently used endcapping reagents, trimethylsilylphosphine has shown to be a 
more effective one, with improved efficiency i.e. reduced peak tailing for all solutes tested, 
compared to phases treated with trimethylchlorosilane, hexamethyldisilazane, or a 




CH3 (CH2)17 –; Octadecyl  
CH3 (CH2)7 - ;   Octyl 
C6H5 (CH2)3 - ;  Phenyl 
CH3 (CH2)3 - ;   Butyl 
CN (CH2)3  - ;   
Cyanopropyl 
 
Table 1. Non-polar functional groups ranked on declining hydrophobicity[1] 
The main disadvantage of silica-based stationary phase is that only mobile phases with pH 
range 2-8 can be used, due to the instability of siloxane bonds. However, polymeric-based 
and zirconium-based stationary phases with wide pH stability (1-11) are now available in 
market[12]. 
 
Figure 3.6 Derivatized silica with C18[19] 
 
 
Mobile phase. The polar nature of mobile phase in RP-HPLC consists of mixtures of water 
and an organic solvent miscible with water. The strength of the mobile phase is determined 
according to the choice of organic solvent and its’ percentage in the aqueous solution. Since 
the stationary phase is of non-polar nature, the increase of organic content, increases the 
strength of mobile phase, therefore desorbing the analytes from the hydrophobic stationary-
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phase surface will result in shorter retention of compounds in column. The organic part of 
mobile phase is usually methanol, acetonitrile or tetrahydrofuran (their concentration ranging 
from ca. 15-90%) of etc. When performing a separation using a multi-solvent mobile phase 
system of these organic modifiers, the average retention times will be somewhat similar for 
all three of them, however the elution order between substances will be somewhat different 





Pumps are devices used to deliver the mobile phase at a constant flow rate into the column. 
They consist of piston(s), which are moved back and forth by the motor cam through the 
cylinder where the mobile phase enters through the inlet valve. When the piston is moved 
back the outlet valve closes and the mobile phase enters the cylinder; when the piston is 
moved forward the outlet valve opens forcing the entrance of mobile phase into the column. 
During pumping, the fluid flow pulsates, adding extra noise in the detector signal; therefore 
pulse dampeners are used to keep the fluid flow smoothly[1]. 
  
Figure 3.7. Cross-sectional view of pump work principle[20] 
When a constant composition of mobile phase is pumped through the column this elution is 
called isocratic. Conversely, when the composition of mobile phase is changed during the 
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analysis i.e. the analysis starts with a mobile phase of weaker eluting strength and it increases 
during the process, this is called gradient elution. The advantage of the gradient elution 
stands on the shortage of analysis time with better peak shapes, when components with big 
difference in retention times are being analyzed. The faster eluting analytes will have enough 
time for retention, thus proper separation and the later eluting substances will elute faster and 




LC detectors give a visual representation of the sample being analyzed, by converting their 
response into electrical signals. These signals are depicted in chromatogram in the shape of 
peak areas and peak heights, which correspond to the concentration or masses of analytes. 
Depending on the chemical structure of substance being analyzed there are several detectors 
employed for detection in HPLC analysis: Spectrophotometric, Fluorescence, Mass 
spectrometric, Light Scattering. 
Among these, the spectrophotometric and mass spectrometric detectors are the most 
commonly used. 
 
Spectrophotometric- UV/VIS detectors 
 
UV detectors are the most widely used detectors for both qualitative and quantitative 
determination on pharmaceutical analysis. Their frequent utilization as HPLC detector is 
based on their high sensitivity, ease of use and good stability. The principle of UV 
spectrophotometric detection relies on the absorption of UV light by the analyte. The Beer’s 
law explains the absorption of radiation by a solution: 
                                                        
Equation 8. Beer's law 
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According to this law the absorbance (A) is proportional to the path length through which the 
radiation passes (l) and the concentration of the substance in the solution (c). (ε) is the molar 
absorptivity of the substance which is constant and specific for every molecule.  
The detector consists of a lamp that generates the radiation through the analyte in the flow 
cell. Depending on the substance to be detected there are two types of lamps used: the 
deuterium lamp- able to emit continuum light on wavelength range 190-400 nm, suitable for 
molecules containing a chromophore; and the tungsten lamp – which emits radiation at higher 
wavelengths of visible range up to 700 nm. On a Variable UV detector a monochromator 
ensures the correct direction of one selected wavelength of light to pass through the flow cell. 
Whereas on a Photodiode Array detector a polychromatic radiation is passed through the 
flow cell and the transmitted light is split in an optical lattice into the individual wavelengths, 
which can be measured by a number of photodiodes, giving a full UV spectrum of a peak in 
order to identify a substance[1]. The light sensor collects the maximum generated signal 
passed through the flow cell, which is electronically inverted by the data system resulting in 
the appearance of a positive peak in the chromatogram[21]. 
 
             
Figure 3.8. A Variable UV detector;                                        Photodiode Array UV detector 
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The principle of quantitative analysis using UV detector is based on using the specific 
absorbance of the substance to calculate the unknown concentration as percentage (%), which 
is defined as:  
 
    
       
 
   
  
                                      Mr  - relative molecular mass (molar mass) 
Equation 9. Specific absorbance[1] 
This refers to the absorbance of a solution containing 1g of the substance dissolved in 100ml 
of solvent measured at defined wavelength at a path of 1cm[1].  
The principle for qualitative analysis using UV detector relies on identification of unknown 
molecules using a reference substance with identical absorption spectrum. The absorption of 
a substance is recorded as a function of wavelength[1]. Although a very useful method for 
identification, it is important to be careful on concluding the identification only by UV 
spectrophotometry due to similarities of different substances on their absorption spectrum. 
 
Mass spectroscopy detector 
Despite the high cost of instrument the mass spectroscopy detector has become very popular 
in liquid chromatography as a detection device in drug bio-analysis, environmental and 
pharmaceutical analysis. Its’ high selectivity and sensitivity for identification and 
quantification of samples of low concentration and complex matrixes makes mass 
spectroscopic detector the detector of choice now days. The principle stands on ionization of 
sample with subsequent separation of ions based on their mass to charge ratio (m/Z).  
Each MS detector consists of three main parts[12]: 
 The sample ionization source, achieved by one of a variety of methods: 
atmospheric pressure ionization (API), electrospray ionization (ESI), 
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atmospheric pressure chemical ionization (APCI) or atmospheric pressure 
photoionization (APPI)/ 
- The analyzer separates the ions according to their m/z under an electromagnetic field. 
There are several types of mass analyzers: quadruple mass filter, ion trap mass 
analyzers, time-of-flight mass analyzer etc. Each analyzer has it’s own special 
characteristics and applications, as well as its own benefits and limitations[22]. 
- The detector records the charge induced when the ion passes by or the current 
produced when an ion hits a surface. The current generated by the passage of the ions 
is in turn amplified by an amplifier, which transfers the ratio output in a data 
acquisition system. 
 











3.2 Ultra-fast performance liquid chromatography vs. HPLC 
3.2.1 UPLC 
The latest evolution in development of ultra-fast performance chromatography from 
conventional HPLC exploits the benefit of this state-of-the art technique in the field of 
analytical science in many folds. While HPLC is a deep-rooted technique for analysis of 
pharmaceutical compounds, it still has some shortcomings when it comes to analysis of high 
complexity samples, for example: samples containing around 0,1% relative impurities require 
high sample capacity in addition to high efficiency in order to be separated sufficiently and 
their concentration to be reliably measured[23]. By this saying, the needs for improvement of 
separation efficiency lead to the interest of developing new columns that would be able to 
generate higher resolution between the individual analytes in a sample and possibly reduce 
the analysis time. The advancement of columns used in UPLC has proven to not only 
increase the efficiency of separation of compounds, but also have satisfactory results of 
analysis in increased flow rates and linear velocities.  
3.2.1.1 The sub-2 μm particles 
 
The reduction in the densely packed particles’ size inside the columns is the breakthrough 
strategy that implemented the basics of UPLC analysis. In comparison to HPLC particles’ 
size (3 μm, 5 μm, 10 μm), the columns used in UPLC are packed with particles of sub-2 μm 
diameter. Since the particle size diameter (dp) is inversely proportional to the number of 





Equation 10. The inverse proportion of particle size (dp) and (N) 
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And resolution (R) is proportional to the square root of N (eq.7), then as the particle size is 
lowered by thrice i.e. from 5 μm to 1.7 μm, N is increased by three and the resolution by 





Equation 11. The inverse proportion of N and W 
Which indicates that the narrower the peaks the better the separation. And as the peak height 
is inversely proportion to peak width, this reduction in particle size also increases the 
sensitivity because narrower peaks are taller.  
Van Deemter curve shows the amplification of chromatographic performance with usage of 
sub- 2 μm particles, enabling the increase of optimum flow (linear velocity) of mobile phase 
to reach the maximum N[25]: 
 
  
Equation 12. Van Deemter curve on different particle size[26]. 
 
This graph shows that the curves are much steeper for particles of bigger size at high linear 
velocities, which means that in order to reduce the analysis time to acceptable values, 
columns packed with common particle size are often operated at linear velocities which do 
not give maximum efficiency[23]; in comparison to the use of columns packed with smaller 
particles size that are able to give high efficiency at high linear velocities. 
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3.2.1.2 The need for high pressures 
 
The main difficulty using smaller diameter packings is that the pressure required to pump the 
mobile phase through the column increases with the square of the particle diameter[27]. This 
necessity lead to the development of special equipment to generate high pressures. In 
comparison to HPLC, which have an operating pressure around 400bar, the UPLC systems 
are characterized with an ultra-high generating pressure of around1000bar (100MPa). The 
pumps are designed to withstand the high pressure while delivering the solvent smoothly and 
reproducibly, during both an isocratic or gradient elution[23]. The injection of sample is 
designated with fast injection cycles (around 25 s a cycle), low sample volumes with 
negligible carryover[28]. The signal detection of peaks in detectors is yet another critical 
adjustment on UPLC system. Considering the ability of columns packed with sub-2 μm 
packed particles to obtain very small peaks in less than one second, the detector sampling rate 
must be high enough to capture enough data points across the peak and have minimal 
dispersion (volume) to ensure a good separation efficiency[25]. Therefore the advancement 
of detectors employed in UPLC, are improved in order to have much higher sensitivities in 
sample detection. The spectrophotometric UV detectors used in UPLC have a smaller flow 
cell volume to maintain the concentration and signal strength.  
 
3.2.1.3 UPLC application 
 
Ever since the UPLC instrument became available in the market, its application was 
increasing vastly. The advantages of short time analysis compared to conventional HPLC, 
without compromising the resolution were a huge incentive for pharmaceutical industry. 
Simultaneous determination of many active ingredients with high chromatographic efficiency 
is now much more convenient using UPLC. A study in procedure transfer from HPLC-MS to 
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UPLC-MS/MS for determination of antidementia drugs in human plasma concluded that both 
techniques are reliable however, the UPLC–MS/MS method is preferable with respect to 
specificity, sensitivity and speed selectivity[29]. Similar comparison study between HPLC 
and UPLC, using identical columns, tubing, flow rates, and pressures, and connected to the 
same tandem mass spectrometer (MS/MS), showed how UPLC can reduce the analysis time 
in half in immunosuppressant monitoring[30]. The use of UPLC is being largely employed in 
food analysis as well, such as: determination of sulfonamide residues present in meat[31]; 
analysis of mutagenic heterocyclic amines (HAs) in complex food samples[32]; 
determination of priority pesticides and transformation products in baby food[33].  
The benefits of UPLC have also proved to provide a reliable technique on environmental 
analysis. The determination of estrogens in different water matrices using UPLC–Q-TOF-MS 
demonstrated the applicability of this newly developed method for quantitative and 
confirmatory analysis of estrogens investigation[34]. 
Forensic analysis studies on determination of amphetamine-type substances and ketamine 
show significant enhancement of separation efficiency in less than 3 min with acceptable 
resolution when using UPLC in toxicological analysis[35]. 
One of the most important utilization of UPLC/MS is its application in drug discovery for 
high-throughput solubility screening of potential drug candidates in the early stages of 
discovery. This method was concluded to be more suitable for high-speed solubility assays 
than traditional HPLC/UV technology[36]. 
3.3  Validation 
According to the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), the analytical procedure chosen for 
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the intended purpose should manifest its suitability of use. There are several performance 
characteristics used in method validation: 
  
Figure 3.10. Performance characteristics used in method validation 
Specificity of an analytical method is defined as its ability to measure accurately an analyte in 
the presence of interference, such as synthetic precursors, excipients, enantiomers and known 
(or likely) degradation products that may be expected to be present in the sample matrix[37]. 
According to the ICH, in chromatographic procedures the chromatograms should 
demonstrate the degree of selectivity and peak purity test based on spectra (e.g. UV/VIS) are 
used to verify that the analyte peak doesn’t correspond to more than one component[1]. 
Precision of a method is the extent to which the individual test results of multiple injections 
of a series of standards agree[37]. It is expressed as the relative standard deviation (% RSD) 
of the mean (m) of a series of measurements: %RSD = RSD/m x 100% [1]. 
Precision can be measured in three levels:  
Repeatability- precision measuring by the same analyst, with the same equipment used, same 
operating conditions over a short period of time, within the same laboratory. According to 
ICH, minimum nine determinations covering the specified range for the procedure should be 
used. 
Intermediate precision (ruggedness) expresses the inter-laboratory variations, performed by 
different analysts and different equipment. 
Validation 







Reproducibility expresses the precision of method between different laboratories in a 
collaborative study[1]. 
Accuracy of a method is the extent to which the test results generated by the method and the 
true value agree.[37]. When assessing an assay of drug substance, accuracy of the method can 
be determined by employing a certified reference substance of known purity, whereas in 
assay of a drug substance in a formulated preparation, a known amount of the drug substance 
(certified reference) is added to the blank formulated product (drug-free)[1]. The accuracy of 
a method is then presented as a percent recovery (ideally 100%), or as the difference between 
the mean and accepted value. According to the ICH, a minimum of nine determinations over 
a minimum of three concentration levels covering the specified range should be used to 
determine accuracy. 
Detection limit shows the minimal analyte concentration that can be detected during analysis 
and is expressed as the concentration of the analyte. In chromatography the detection limit is 
based on the signal to noise ratios (S/N ratio).  S/N ratio is determined by measuring signals 
of samples with known concentrations and the baseline noise of blank samples. Ratios of 3:1 
or 2:1 are generally accepted values for detection limit estimation[1]. 
 
Figure 3.11. S/N ratio[38] 
Quantification limit is the lowest amount of an analyte in sample, which can be quantified 
accurately and precisely. In chromatography, the resulting peak of the analyte (H) should be 
ten times higher than the baseline noise (h) i.e. S/N is 10:1. The quantification limit can also 
be determined by employing the injected samples with decreasing amount of analyte from 
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precision data and the % RSD is plotted against the analyte concentration. The usual criteria 
to define limit of quantitation is set to 20%[1]. 
Linearity The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration of analytes in samples within a given range[37]. 
According to ICH, determination of linearity should be based on a minimum of five 
concentrations, with specified ranges of concentration from 80-120% for assay of active 
substance or formulated product and 50-120% range for determination of impurity. Linearity 
can be evaluated graphically by plotting the deviations from the regression line versus the 
concentration or versus the logarithm of the concentration[37]. 
Robustness is the evaluation the effect of variations of different operational parameters on 
the analytical method. Parameters like pH, column temperature, flow rate, detection 
wavelength etc., are changed and their variation is quantified. This difference should be 
within the specified range of robustness for the method to be considered correctly validated. 
3.3.1.1 System suitability test 
 
It is a test of continuous evaluation of robustness during the method development. The mostly 
used parameters in chromatographic procedure are: Number of theoretical plates (N), 
Retention factor (k’), Resolution (RS), Relative Retention and Asymmetry factor (A). In 
Ph.Eur and USP the requirements for system suitability test of HPLC methods are typically: 
 %RSD of peak areas or peak heights are <1% (for drug substance assay) 
 The resolution (RS) is >2 
 Asymmetry factor (A) is in the range 0.8-1.5 
 The number of theoretical plates (N) are larger than 2000 (for HPLC) 








3.3.2 Bromhexine Hydrochloride  
 
 
3.3.2.1 Physical and Chemical Properties 
 
Molecular formula: C14H20Br2N2, HCl 
Molecular weight: 412.6 
CAS Registry: 611-75-6 
Chemical name: N-[2-Amino-3,5-dibromobenzyl]-N-methylcyclohexanamine hydrochloride. 
Appearance and solubility: A white or almost white crystalline powder. It exhibits 
polymorphism. Very slightly soluble in water; slightly soluble in alcohol and in 





                               
                                Figure 3.12. Chemical structure of Bromhexine Hydrochloride 
                          
3.3.2.2 Pharmacology  
 
Bromhexine Hydrochloride is a benzylamine derivative with expectorant/mucolytic activity. 
Its expectorant mechanism is explained by its ability to increase the water content in the 
airways secretion, thus hydrating the content of sputum, making it less sticky and easier for 
the bronchial cilia to expectorate the phlegm. The “mucoactive” effect reduces the viscosity 






It’s pharmacological effect makes Bromhexine a useful prescribed medication for respiratory 
disorders associated with exorbitant mucus production. Several data explain the effect of 
Bromhexine in chronic bronchitis, which show that in patients with less severely impaired 
ventilatory capacity mucolytic therapy with Bromhexine is capable of producing objective as 
well as subjective improvement[40]. Unfortunately, the treatment didn’t show satisfactory 
results in patients with more severely impaired respiratory capacity – patients with severely 
impaired ventilatory capacity when treated with Bromhexine did not improve objectively, but 
subjectively they felt better[40]. Some clinical observations showed that the usage of 
Bromhexine resulted in remission of lacrimal and salivary secretions in patients with 
Sjogren’s syndrome. The usual dose of oral Bromhexine in the treatment of Sjogren’s 
syndrome has been 16 milligrams orally three times daily.[41] 
3.3.2.4 Pharmacokinetics 
 
Bromhexine Hydrochloride is rapidly absorbed from the gastrointestinal tract and it 
undergoes extensive first-pass metabolism in liver. Peak serum concentrations of Bromhexine 
occur approximately 1 hour following oral administration[42]. When administered orally, the 
bioavailability is around only 20%, because it bounds highly to plasma proteins and has a 
wide distribution on body tissues. It is excreted in urine mainly as metabolites, with 
Ambroxol being pharmacologically active among them.  
3.3.2.5 Adverse effects 
 
During Bromhexine treatment infrequent gastrointestinal disturbances (nausea, epigastric pain, 
vomiting and diarrhea) have been noticed. A transient rise in serum aminotransferase values has been 




4.1 Method development 
A new method for determination of impurity content of Bromhexine Hydrochloride active 
pharmaceutical ingredient was developed using an Ultra High-Performance Liquid 
Chromatography. Bromhexine HCl (API) powder used for analysis was retrieved from the 
producer of preparation Bromhexine GALMED 8 – Galmed. The analytical procedure was 
transferred from the conventional method using HPLC described in European Pharmacopeia 
for determination of related substances on Bromhexine HCl (API). From the sample of test 
solution, two reference solutions were prepared:  
 Reference solution (a) used for testing the optimization of chromatographic 
conditions on UPLC by evaluating the resolution (RS), tailing factor (TF) and 
backpressure (P). 
 Reference solution (b) used for the calculations during method validation. 
 
4.1.1 Sample preparation 
Test solution 
The test solution was prepared according to the procedure in pharmacopeia: 
50 mg of Bromhexine Hydrochloride was dissolved in methanol R. This solution was further 
diluted to 10.0 mL using the same solvent[39]. 
Reference solution (a) 
According to pharmacopeia, 5 mg of Bromhexine impurity C CRS was dissolved in 
methanol. 1 mL of test solution was added and it was further diluted to 10.0 mL with the 
same solvent[39]. Due to restricted availability of this impurity in our laboratory, only 0.3 mg 
impurity C was used to prepare this reference solution with the same resulting concentration 
as the reference solution instructed by pharmacopeia. So 0.3 mg impurity C was dissolved in 
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methanol and the total volume of solution in order to have the same concentration was 
calculated to be 0.6 mL (as opposed to 10 mL). The calculated amount of test solution to be 
added was 0.06 mL; hence 0.54 mL of methanol was added to round up to 0.6 mL of 
reference (a) solution. 
Reference solution (b) 
1 mL of test solution was diluted to 100.0 mL methanol R. 1 mL of this solution was further 
diluted to 10.0 mL with the same solvent[39]. 
4.1.2 Solvents and reagents 
Mobile phase 
The composition of mobile phase used was also employed according to the procedure in 
pharmacopeia: 
0.50 mL of phosphoric acid R was mixed in 950 mL of water R. The pH was adjusted to 7.0 
with triethylamine R (about 1.5 mL) and was diluted to 1000 mL with water R. 20 volumes of 
this solution were mixed with 80 volumes of acetonitrile R[39]. 
4.1.3 Optimization of chromatographic conditions 
“Prominence UFLC” instrument by Shimadzu Corporation  (Japan) was utilized to conduct 
analysis.  The differences between HPLC columns used in analytical procedure from 
pharmacopeia and the UFLC columns used in our analysis are shown on the table below: 
Column specifications HPLC (in Ph.Eur) UFLC 
Stationary phase description End-capped C18 silica gel (3 μm)  Kinetex 1.7 μm 
C18, 100A 
Column length 120 mm 150 mm 
Column Internal diameter 4.6 mm 2.1 mm 
Figure 4.1. Physical dimensions differences between HPLC and UFLC columns 
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Optimization was tested on reference (a) solution. Two approaches were used to determine 
the chromatographic conditions for the new method, in order to utilize optimal conditions for 
analysis: 
1. Adaption of different temperatures (from 25-40°C) at a flow rate 0.35 mL/min,  
2. Adaption of different flow rates (from 0.35-0.6 mL/min) at 40°C temperature 
Injection volume was 1.6μl. The optimization was based on resulting resolution between the 
peaks of Impurity C and Bromhexine Hydrochloride, the tailing factors of peaks and the 
backpressure limit. 
 
1. Adaption of different temperature adjustments (from 25-40°C) at a flow rate 
0.35 mL/min 
 Reference (a) solution was injected once on four temperature adjustments of: 25°C, 30°C, 
35°C and 40°C. The parameters depicting the method efficiency are shown on the table 
below: 
 
t (°C) at flow 
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Figure 4.3. Resolution plotted against temperature ranges 
 
   
Figure 4.4. Tailing factors of Bromhexine HCl and Impurity C plotted against different temperature 
adjustments 
   































2. Adaption of different flow rates (from 0.35-0.6 mL/min) at 40°C temperature 
 
Similarly, a single injection of reference (a) solution on six different flow rates at 40°C 
column temperature shows the resulting values of resolution, tailing factors and 
backpressure: 
 
Flow rate (mL/min) 
 at 40°C  
Temperature 







   1.108    0.754       48.6 
0.4        18.883     1.104     0.751       56.1 
0.45        18.046     1.099     0.752       63.7 
0.5 17.545 
 
    1.088     0.747       69.7 
0.55       16.093     1.04     0.733       77.5 
0.6       15.397     1.07     0.752       83.2 




   











   
Figure 4.8. Tailing factors of Impurity C and Bromhexine on different flow rate adjustments 
 
   
Figure 4.9. Backpressure on different flow rate adjustments 
 
Based on the results obtained from these two approaches adopted to determine optimal 
chromatographic conditions for the newly developed method, it was concluded that the 
analysis conducted with flow rate 0.5 mL/min at column temperature of 40°C and 
injection volume 1.6μl showed the most optimal combination of resolution between the 
Impurity C and Bromhexine HCl peaks, their tailing factors and column backpressure limit. 
Compared to the method in Ph.Eur, the time of analysis was 3 times shorter; peak symmetry 
was in the limit (0.8-1.5), resolution of Impurity C and Bromhexine HCl was higher than 12 
(which is the limit for system suitability test in Ph.Eur) and the pressure was below the limit 




















4.2 Method Validation 
4.2.1 Linearity 
Determination of linearity was based on seven different concentrations within a range of 
0.02-0.3 % of diluted test solution. Each solution was injected twice and their average areas 
were used to evaluate linearity graphically by plotting the deviations from the regression line 
versus the concentrations. 
Sample preparation 
1 ml of test solution was completed to 100 mL of methanol R. 
0.2; 0.5; 1; 1.5; 2; 2.5; 3 ml from this solution was diluted to 10 ml with the same solvent.  
The resulting concentration of Bromhexine HCl (BHX) in solutions of a range from 0.1 μm 
(0.02%)-1.5 μm (0.3%) were expressed in percentage: 
Linearity L1a L1 L2 L3 L4 L5 L6 
BHX  % 0.02 
 
0.05 0.1 0.15 0.2 0.25 0.3 
Figure 4.10. Seven concentrations of test solution used to determine Linearity 
Areas of injection of seven concentrations of Bromhexine HCl test solution and the average for two 
injections of each concentration are shown below: 
Bromhexine             Area       Average Area 
L_01a_001 5077  
L_01a_002 5148 5112.5 
L_01_001 10648  
L_01_002 10535 10591.5 
L_02_001 21075  
L_02_002 21052 21063.5 
L_03_001 31138  
L_03_002 31727 31423.5 
L_04_001 42886  
L_04_002 43097 42991.5 
L_05_001 54304  
L_05_002 54329 54316.5 
L_06_001 62698  
L_06_002 62602 62650 
 Figure 4.11. Linearity concentrations; areas; AVG area of two injections. 
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The regression line is calculated by the method of least square where y is the peak area and x 
is the concentration of Bromhexine (BHX) in test solution. The square of the correlation 
coefficient R
2
= 0.99877, shows the high linearity of the peak areas with the corresponding 
concentrations. 
 
   







4.2.2 Detection limit 
The detection of lowest concentration of test solution was found using the signal-to-noise 
ratio (S/N), which shows the ratio between the peak height (H) and baseline noise height (h). 
Since for detection of lowest amount of analyte S/N=2, then S/N=H/h=2. Using the 
chromatogram from lowest concentration (0. 1μg/mL) solution in linearity, the value of H 
was measured to be 5.5cm, and h was 0.8 cm. 
 
y = 210589x + 403.97 















Figure 4.13. Chromatogram of BHX HCl test solution with lowest c (μg/mL) obtained from linearity 
testing. 
 According to the formula above: H= 2h the detection limit corresponds to the solution with 
peak height H= 2 x 0.8= 1.6cm and the concentration of test solution with peak height of 1.6 
cm is: 
                       0.1μg/mL x (1.6cm / 5.5cm) = 0.03μg/mL 
This concentration accounts for 0.006 % 
 
4.2.3 Quantification limit 
The limit of quantification was determined similarly applying the signal to noise ratio (S/N) 
obtained from chromatogram of lowest concentration (0.1μg/mL) solution from linearity. 
Since the quantification limit is at S/N ratio of 10, the peak height (H) is:  
                         H=10 x 0.8cm = 8cm,  
    Then:            0.1μg/mL x (8cm / 5.5cm) = 0.1μg/mL 
 
From the above calculations, the quantification limit was found to be 0.1μg/mL, which 





































































Repeatability was used to express the precision of method. The content of unknown 
impurities present on 6 samples of a ≈ 0.5 mg/mL of Bromhexine HCl (API) test solution 
(100%) was determined using two methods: 
 The external standard method (as instructed in pharmacopeia) by employing the 
reference (b) solution with percentage area of Bromhexine HCl as 0.1% of the 
(100%) test solution to calculate the average percentage areas of 2 injections of 
unknown impurities from 6 six test solutions of similar concentration. 
 The normalization method by directly calculating the average area percentage of 
impurities obtained from 2 injections of 6 test solutions. 
Relative standard deviation (RSD 100%) was calculated to determine the precision of 
method. 
 Sample preparation 
50 mg of Bromhexine HCl was measured six times and diluted to 10 mL with methanol R. 
Precision 
samples 
P_01 P_02 P_03 P_04 P_05 P_06 
Weights 
(mg) 
49.70 49.99 49.76 50.27 49.84 49.81 
Figure 4.14. Six measurements of BHX HCl for preparation of precision samples 
 
The tables below show the values of peak area percentage of Bromhexine HCl in ref. (b) 
solution and content of two unknown impurities present in the test solution calculated by both 
methods: external standard vs. normalization method. The resulting RSD % values are also 




Reference (b) solution AVG area for 2 injections Area %  
Bromhexine (BHX) 21223.5 100 









AVG area % 
(external standard 
method) 
AVG area % 
(normalization 
method) 
P_01 9629.5 0.045 0.048  
P_02 10047 0.047 0.049 
P_03 9159.5 0.043 0.046 
P_04 9836 0.046 0.047 
P_05 10111 0.048 0.050 
P_06 10395 0.049 0.052 




Unknown Imp. 1 AVG area % for 6 samples RSD % 
External standard method 0.046 4.37 
Normalization method 0.048 4.50 













AVG area % 
(external standard 
method) 
AVG area % 
(normalization 
method) 
P_01 4939.5 0.023 0.024 













Figure 4.18. Content of unknown impurity 2. 
Unknown Imp. 2 AVG area % for 6 samples RSD % 
External standard method 0.023 
 
5.07 
Normalization method 0.024 
 
4.81 





Six samples of test solutions containing a known amount of Impurity C added were used to 
determine whether the results generated by the method and the true value agree. The true 
value was determined by employing the concentration of prepared solution of Impurity C in 
10 mL methanol R (c=0.172 mg/mL) to calculate the concentration of Impurity C added 
(0.02 mL) in 1.02 mL of total volume of test solution. Lastly, accuracy was expressed as the 







6 test solutions were prepared in the same manner as samples for precision calculation. 20μl 
(0.02 mL) of Impurity C solution with concentration 1.72mg / 10 mL was added to 1 mL of 
test solution. 
The resulting volume of test solution for accuracy was 1.02mL. 
 
The tables below show the results for accuracy determination using the external standard 
method to calculate the Impurity C content: 
 
Bromhexine average peak area in accuracy testing: 
Reference (b) solution AVG area for 2 injections Area %  
Bromhexine (BHX) 21037 
 
100 
Figure 4.20. Bromhexine peak area in ref. (b) solution for accuracy testing. 
 












A_01 15126.5 0.072 0.00359 0.00337 106.60 
A_02 14067 0.067 0.00334 0.00337 99.14 
A_03 13854 0.066 0.00329 0.00337 97.63 
A_04 13928 0.066 0.00331 0.00337 98.16 
A_05 14284.5 0.068 0.00339 0.00337 100.67 
A_06 14291.5 0.068 0.00339 0.00337 100.71 
AVG 
recovery % 
    100.48 
 









Accuracy determination using the normalization method to calculate the Impurity C content: 
 








A_01 15126.5 0.0715 0.00357 0.00337 106.00 
A_02 14067 0.069 0.00345 0.00337 102.30 
A_03 13854 0.0675 0.00337 0.00337 100.07 
A_04 13928 0.068 0.00345 0.00337 100.81 
A_05 14284.5 0.069 0.00345 0.00337 102.30 
A_06 14291.5 0.0685 0.00342 0.00337 101.55 
AVG 
recovery % 
    102.17 
 





The selectivity of method was tested in order to validate the method in case when 
Bromhexine HCl preparations (as opposed to API) are to be analyzed. 
A batch with test solution (from precision and accuracy testing), reference (a) solution, 
reference (b) solution and a placebo, was run in order to evaluate the selectivity of the 
method. The peaks from each solution on the resulting chromatograms were investigated for 
any interference between retention times of substances present on solutions. 
Sample preparation 
The placebo solution was prepared according to the producer of Bromhexine HCl preparation 
(Bromhexine GALMED 8).  6.5 mL of placebo solution were completed to 10 mL of 
methanol R, in order to correlate to the 5mg/mL concentration of Bromhexine HCl in the test 




Figure 4.23. Comparison of chromatograms for method selectivity 
As seen on the picture above, no peaks from placebo interfere with any peak of impurities 
and the active substance. 
 
4.2.7 Results and discussions 
The conventional HPLC method guided by European Pharmacopeia for determination of 
related substances of Bromhexine Hydrochloride (API) was successfully transferred to UFLC 
method for analysis. The newly developed method using UFLC with columns of sub-2 μm 
particle size of stationary phase and subsequently increased flow rate 0.5 mL/min at column 
temperature of 40°C was properly validated in order to ensure the suitability of the analytical 
procedure. The results for each validation method conducted are discussed below: 
 
-System suitability test: During the validation procedure, reference (a) solution was injected 
with every batch to ensure the suitability of test by measuring the resolution between the 
peaks of Bromhexine HCl and Impurity C. According to the procedure in pharmacopeia the 
minimum value of resolution between those peaks should be 12.  The resolution value in our 























analysis was 23, which accounts for higher efficiency of the UPLC columns versus HPLC 
columns. Except resolution, the tailing factor was also used to ensure the suitability of test. 
The peak symmetry of both Impurity C and Bromhexine were within the limit range 0.8-1.5 
during the whole analysis. 
-Linearity of the analytical procedure was affirmed based on the resulting correlation factor 
of R
2 
=0.99877 (Figure 4.24.), which shows the high proportionality of seven concentrations 
(within a range of 0.02-0.3 mg/mL) of Bromhexine HCl in test solution to their 
corresponding areas in chromatogram. 
According the European Pharmacopeia for Bromhexine HCl impurity content testing, any 
impurity peak area should not be greater than twice the area of the principal peak in 
chromatogram obtained from reference (b) solution (0.2%) [39]. Based on the results 
obtained from precision and accuracy, the impurity content in Bromhexine HCl was within 
the limited percentage. 
-Precision. Two methods were employed to calculate the impurity content in order to 
evaluate precision (and accuracy): the external standard method and the normalization 
method. Based on the results obtained from both methods, we can say that both of them are 
suitable to give satisfactory results regarding the limits of impurity content. However, the 
external standard method can be considered less favorable for an analyst for a practical 
reason i.e. the necessity of preparation of the reference (b) solution needed for calculation of 
impurity content, as opposed to the normalization method where the impurity % was 
calculated directly from the peak areas in chromatograms. 
According to the ICH the acceptable value for relative standard deviation (RSD%) in 
evaluation of precision in the case of impurity content in the active substance in 
concentration range from LOQ (0.02 % in our case) to 0.1% of impurity is 7%. 
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The tables below show the comparison of two methods used to evaluate the results of RSD % 
obtained from our analysis of precision testing versus the acceptable values of RSD % for 
precision determined by ICH: 
 
-External method standard: 
Impurities AVG imp. content (%) RSD %  RSD % (limit 
by ICH) 
Unknown Imp. 1 0.046 4.37 7% 
Unknown Imp. 2 0.023 5.07 7% 





Impurities AVG imp. content (%) RSD %  RSD % (limit 
by ICH) 
Unknown Imp. 1 0.048 4.50 7% 
Unknown Imp. 2 0.024 4.81 7% 
Figure 4.26. RSD limits for precision (normalization method) 
 
-Accuracy. Similarly as in precision testing, the two above mentioned methods for 
calculation of impurity % showed satisfactory recovery results within the required limits. 
Since the limits for determination of impurity content (Ci) for active substance is LOQ%≤ Ci 
≤ 0.1%, the recovery of impurities should be 85-115%.  
The tables below show the comparison of two methods used to evaluate the results of 
recovery (%) of Impurity C added to measure accuracy of method. Obtained values of 
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recovery from our analysis versus the acceptable values of recovery % for accuracy testing 
by ICH are as follow: 







Normalization method 102.173 85-115 
Figure 4.27. Differences on recovery values between two methods. 
-Selectivity. In figure 4.28, the comparison of chromatograms of placebo, test solutions (from 
accuracy and precision), reference (a) solution and reference (b) solution show no peak 
interference of substances present in placebo solution with Bromhexine HCl or any of 
impurity peaks, proving the selectivity of method, hence the method is suitable for analysis of 
Bromhexine HCl preparations as well. 
4.2.8 Conclusion 
The development of a new method for determination of related substances in Bromhexine 
HCl active substance using Ultra High-performance Liquid Chromatography, with the aim of 
decreasing the analysis time and sparing the usage of large volumes of mobile phase while 
ensuring satisfactory peak resolution and overall chromatographic performance was 
successfully accomplished. The analytical tests conducted to assure the suitability of method 
proved that the newly developed method was properly validated and can therefore be used as 
an alternative analysis to HPLC. In comparison to the conventional method guided by 
European Pharmacopeia using HPLC, the utilization of UPLC in this analysis showed a much 
higher chromatographic efficiency. In conclusion, despite the high cost of this 
chromatographic instrument, its numerous advantages account for its high applicability in 
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